KDM2B-IN-2（Cat No.:I044384）is a selective small-molecule inhibitor targeting KDM2B, a histone demethylase involved in the epigenetic regulation of gene expression. By inhibiting the demethylation of H3K36me2, KDM2B-IN-2 disrupts chromatin remodeling and transcriptional repression linked to oncogenesis. This compound shows promise in cancer research, particularly in malignancies where KDM2B is overexpressed, such as certain leukemias and solid tumors. KDM2B-IN-2 enables detailed studies of histone modification pathways and supports the development of targeted epigenetic therapies. It demonstrates strong cellular activity and potential for both in vitro and in vivo applications.